stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Gross margin
ADMA Biologics Inc's gross margin over the twelve months to 30 September 2026 was 68.5%, up 11.1 percentage points from fiscal 2025 (57.4%). Over the past ten years it has ranged from −148.4% (fiscal 2018) to 57.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 57.4% | 5.91 |
| FY2024 | 51.5% | 17.04 |
| FY2023 | 34.4% | 11.55 |
| FY2022 | 22.9% | 21.44 |
| FY2021 | 1.45% | 46.62 |
| FY2020 | −45.2% | (10.57) |
| FY2019 | −34.6% | 113.82 |
| FY2018 | −148.4% | (120.28) |
| FY2017 | −28.1% | (68.48) |
| FY2016 | 40.3% | 0.41 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 70.8% | 1.45 |
| Jun 2026 | 69.4% | (1.17) |
| Mar 2026 | 70.5% | 6.71 |
| Dec 2025 | 63.8% | 7.48 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| VCEL Vericel Corporation compare | 74.5% |
| ADMA ADMA Biologics Inc | 68.5% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement